Perreault S, Ong H, du Souich P
Department of Pharmacology, Faculty of Medicine, University of Montreal, Québec, Canada.
J Pharmacokinet Biopharm. 1992 Oct;20(5):461-76. doi: 10.1007/BF01061466.
This study assessed the influence of dose and route of administration on salbutamol kinetics and hypokaliemic effect. Salbutamol plasma kinetics were studied in a first group of 6 rabbits who received 60, 800, and 60 micrograms/kg by the intravenous (iv), oral (po), and intratracheal (it) routes, respectively, at 1-week intervals. A second group of 6 rabbits received 120, 2400, and 120 micrograms/kg of salbutamol by the same three routes. Multiple blood samples were withdrawn to assay salbutamol and potassium. Following iv salbutamol (60 micrograms/kg), total plasma clearance was 82 +/- 5 ml/min per kg, apparent volume of distribution was 5.0 +/- 0.5 l/kg, and terminal half-life was 41 +/- 2 min. Similar values were estimated when 120 micrograms/kg of salbutamol was administered iv or was given po or it. The bioavailability of po and it salbutamol was approximately 1 and 20%, respectively. For the first group, the maximal decrease in plasma potassium elicited by salbutamol was 0.80 +/- 0.19, 0.48 +/- 0.22, and 0.78 +/- 0.46 mmol/l, and for the second group, maximal decrement was 1.31 +/- 0.37, 0.70 +/- 0.24, and 0.84 +/- 0.17 mmol/l for the iv, po, and it routes, respectively. Compared to salbutamol peak plasma concentrations, maximal decrease in plasma potassium appeared between 60 and 108 min later for the iv route, 90 and 25 min later for po and it routes, and for this reason, the hypokaliemic effect was not associated to salbutamol plasma concentrations. The hypokaliemic effect was dependent upon the route, e.g., po > it > iv.(ABSTRACT TRUNCATED AT 250 WORDS)
本研究评估了给药剂量和途径对沙丁胺醇动力学及低钾血症效应的影响。在第一组6只兔子中研究了沙丁胺醇的血浆动力学,它们分别按静脉注射(iv)、口服(po)和气管内(it)途径,每隔1周接受60、800和60微克/千克的沙丁胺醇。第二组6只兔子通过相同的三种途径接受120、2400和120微克/千克的沙丁胺醇。采集多份血样以检测沙丁胺醇和钾。静脉注射沙丁胺醇(60微克/千克)后,血浆总清除率为82±5毫升/分钟·千克,表观分布容积为5.0±0.5升/千克,终末半衰期为41±2分钟。静脉注射120微克/千克的沙丁胺醇或口服或气管内给药时,估算得到的数值相似。口服和气管内给药的沙丁胺醇生物利用度分别约为1%和20%。对于第一组,沙丁胺醇引起的血浆钾最大降幅分别为0.80±0.19、0.48±0.22和0.78±0.46毫摩尔/升,对于第二组,静脉注射、口服和气管内给药途径的最大降幅分别为1.31±0.37、0.70±0.24和0.84±0.17毫摩尔/升。与沙丁胺醇血浆峰值浓度相比,静脉注射途径的血浆钾最大降幅出现在60至108分钟后,口服和气管内给药途径分别出现在90至25分钟后,因此,低钾血症效应与沙丁胺醇血浆浓度无关。低钾血症效应取决于给药途径,例如口服>气管内给药>静脉注射。(摘要截选至第250个单词)